文献速递传染病防控与疫情报告免疫规划

羊用FhSAP2疫苗候选的免疫原性评估:无保护效力

Assessment of the Fasciola hepatica saposin-like protein 2 (rFhSAP2) vaccine candidate in sheep: Immunogenicity without protective efficacy.
PubMed 文献 · Vaccine · 2026-10-06

疫苗组虫负荷降低16.4%(p>0.05),粪卵数降低8.9%–34.5%(p>0.05),虫卵活力仍高(88.9%–91.3%),但诱导了强而持久的体液免疫应答。结论:rtFhSAP2在羊中高度免疫原性,但未转化为显著保护。

要点

  • rtFhSAP2加Montanide ISA 201 VG在羊中诱导强而持续的IgG、IgG1和IgG2应答。
  • 疫苗组虫负荷降低16.4%,粪卵数降低8.9%–34.5%,均无统计学显著性(p>0.05)。
  • 粪卵活力组间无显著差异(88.9%–91.3%),胆囊来源卵活力疫苗组较低但无显著性。

核心结论

  • rtFhSAP2加Montanide ISA 201 VG在羊中高度免疫原性,但未产生显著抗肝片形吸虫保护。

研究设计与样本

  • 疫苗组皮下接种400 μg rtFhSAP2加Montanide ISA 201 VG,共三次,间隔四周。
  • 免疫后口服200个肝片形吸虫囊蚴攻击,评估虫负荷、粪卵计数和虫卵活力。

主要发现

  • 疫苗组虫负荷较感染对照组降低16.4%(p>0.05)。
  • 粪卵计数降低范围为8.9%至34.5%(p>0.05)。
  • 各组粪卵活力范围为88.9%至91.3%(p>0.05)。
  • 疫苗组胆囊来源虫卵活力为56.9%,感染对照组为75.9%,佐剂对照组为73.6%(p>0.05)。
  • 疫苗组IgG和IgG1水平在第4–24周和第4–32周显著高于两个对照组,IgG2在第4–24周显著升高但低于IgG1。

临床怎么用

  • 当前rtFhSAP2配方虽免疫原性强,但不足以作为羊肝片形吸虫病的保护性疫苗。
  • 评估疫苗候选需同时关注免疫原性与实际保护效力,不能仅凭抗体应答判定。

局限性

  • 样本量较小(每组7只),可能影响统计效能。
  • 未报告其他潜在保护相关指标或长期观察数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fasciolosis caused by Fasciola hepatica is an economically important parasitic disease of livestock and a major zoonotic disease in humans. Vaccination is a promising strategy to reduce the impact of fasciolosis and dependence on fasciolicides. Saposin-like protein 2 (FhSAP2) has previously shown high immunogenicity and reductions in fluke burden in experimental animal models; however, its efficacy has not been evaluated in sheep. Twenty-one female sheep were randomly assigned to three groups (n = 7): vaccinated, adjuvant control, and infection control. The vaccinated group received 400 μg of rtFhSAP2 formulated with Montanide ISA 201 VG, the adjuvant control received Montanide ISA 201 VG alone, and the infection control received saline. Animals received three subcutaneous immunizations at four-week intervals and were subsequently challenged orally with 200 F. hepatica metacercariae. Vaccine efficacy was evaluated based on fluke burden, fecal egg counts, and egg viability. Antigen-specific IgG, IgG1, and IgG2 antibody responses were assessed by ELISA. Vaccination with rtFhSAP2 resulted in a 16.4% reduction in fluke burden compared with the infection control group (p > 0.05). Reductions in fecal egg counts ranged from 8.9% to 34.5% (p > 0.05). Fecal egg viability remained high, ranging from 88.9% to 91.3% among groups (p > 0.05). Gallbladder-derived egg viability was lower in vaccinated sheep (56.9%) than in the infection control (75.9%) and adjuvant control (73.6%) groups (p > 0.05). Vaccination induced a strong and sustained humoral response. IgG and IgG1 levels were significantly higher in vaccinated sheep than in both control groups from weeks 4-24 and 4-32, respectively. IgG2 levels were also significantly higher from weeks 4-24, although the response was lower than that of IgG1. Overall, rtFhSAP2 formulated with Montanide ISA 201 VG was highly immunogenic in sheep, but the humoral response did not translate into significant protection against F. hepatica.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Balderas Loaeza AV, Espinoza Gutiérrez BJ, Cruz Mendoza I, et al. Assessment of the Fasciola hepatica saposin-like protein 2 (rFhSAP2) vaccine candidate in sheep: Immunogenicity without protective efficacy. Vaccine. 2026. PMID: 42837893. doi:10.1016/j.vaccine.2026.129223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。